Clinical Trial Update: A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Hu3F8/GM-CSF immunotherapy plus isotretinoin in patients in first remission of high-risk neuroblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Hu3F8 (Hu3F8)
• ISOTRETINOIN (Isotretinoin)
• sargramostim (sargramostim)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 2 | Status: COMPLETED